Stereotaxis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Stereotaxis, Inc. on July 24, 2008, reporting events occurring on July 18, 2008. The filing details a Second Amendment to the Development Alliance and Supply Agreement with Biosense Webster, Inc., originally dated May 7, 2002.
Key Financial Metrics and Obligations
- Immediate Cash Inflow: Biosense Webster agreed to pay Stereotaxis $10.0 million as an advance on revenue share amounts.
- Deferred Expenses: Up to $8.0 million of research and development expenses owed by Stereotaxis to Biosense Webster (including approximately $6.7 million due as of July 1, 2008) will be deferred.
- Interest Rate: Outstanding advances and deferred expenses accrue interest at the prime rate plus 0.75%.
- Repayment Terms: Funds must be repaid by the sooner of December 31, 2011, or an Accelerating Recoupment Event.
- Supplemental Payments: Commencing May 15, 2010, Stereotaxis must make quarterly payments to Biosense Webster equal to the difference between recouped revenue share (excluding irrigated catheters) and $1 million, until the debt is cleared.
Material Changes and Agreement Terms
The amendment restructures the financial relationship between the two companies. The $10.0 million advance is immediately offset by the recoupment of approximately $1.5 million in revenue share due as of July 1, 2008. The remaining balance, along with deferred R&D expenses, is subject to recoupment via future revenue share deductions. The agreement includes specific acceleration triggers based on Stereotaxis raising capital:
- Financing ≥ $50 million: Triggers full acceleration of repayment.
- Financing $40 million - $50 million: Requires repayment of 75% of outstanding funds.
- Financing $30 million - $40 million: Requires repayment of 50% of outstanding funds.
Outlook, Risks, and Contingencies
Intellectual Property Contingency: If Stereotaxis fails to repay all amounts by the Final Payment Date, Biosense Webster receives a non-exclusive, perpetual, fully paid worldwide license to certain Stereotaxis intellectual property necessary to manufacture and sell irrigated and non-irrigated catheters and compatible CARTO Systems. This license terminates if repayment is completed prior to the deadline.
Odyssey Network Rights: Biosense Webster was granted non-exclusive rights to connect to Stereotaxis's Odyssey Network for clinical and technical support. Biosense Webster will pay a fee based on Stereotaxis's fully-loaded cost plus a premium, subject to reduction if lower rates are offered to third parties.
Forward-Looking Statements: The filing includes standard disclaimers that future performance is subject to risks and uncertainties, and the company does not intend to update these statements except as required by law.
Investor Verification Checklist
- Verify the exact amount of the $10.0 million advance received and the immediate offset of the $1.5 million revenue share.
- Confirm the current status of the $6.7 million in deferred R&D expenses and the interest accrual rate.
- Monitor Stereotaxis's capital raising activities to assess the risk of triggering partial or full repayment acceleration clauses.
- Review the terms of the perpetual IP license to understand the potential loss of exclusivity if the debt is not repaid by December 31, 2011.
- Check the press release filed as Exhibit 99.1 for additional management commentary on the strategic impact of this amendment.